Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sialic acid-binding immunoglobulin-type lectin 6 (Siglec-6)
- Target
- Siglec-6
- Molecular classification
- Receptor, Lectins, Type I transmembrane protein, Immunoglobulin superfamily
01
Overview
Siglec-6 is a member of the CD33-related Siglec family, acting as an inhibitory receptor expressed in placental trophoblasts, mast cells, and memory B-cells. It binds sialic acid-containing glycans, particularly α2–6-linked sialosides. Upon ligand binding, ITIM/ITSM motifs in its cytoplasmic domain recruit SHP phosphatases, dampening activation signals. It also regulates cell migration and adhesion. Siglec-6 is overexpressed in CLL cells and colon cancer, making it a target for antibody-based therapies.
- Other names
- SIGLEC6CD33-related Siglec family member
02
Mechanism of action
Inhibition of downstream signaling pathways via SHP recruitment (ITIM/ITSM phosphorylation); blockade of ligand interaction.
03
Biological functions
Immune inhibitionCell adhesionCell migrationSignal transduction
04
Disease associations
Chronic Lymphocytic Leukemia (CLL)Colorectal cancerCancerImmune evasion
05
Safety considerations
Potential off-target effects in healthy tissues (placenta, mast cells, memory B-cells)
06
Interacting drugs
Anti-Siglec-6/CD3 bispecific antibodies
1 more in the full profile.
Beyond the preview
Go deeper on Sialic acid-binding immunoglobulin-type lectin 6 (Siglec-6).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sialic acid-binding immunoglobulin-type lectin 6 (Siglec-6).